Navigation Links
Cancer researchers seek safe reduction of radiotherapy
Date:10/2/2007

University of Manchester scientists will discuss their research aimed at reducing the side effects of radiotherapy without decreasing its effectiveness at the National Cancer Research Institute conference in Birmingham today (Tuesday 2 October 2007).

Around half of patients receive radiotherapy as part of their cancer treatment but the dose is limited by the possibility of causing side effects (toxicity) to the normal tissues and organs that surround the tumour. Some patients are more likely to experience these side effects than others: that is, there is an individual variation in tissue response. Some patients will be very sensitive.

Dr Catharine West, of the University's Cancer Studies research group, and Dr Neil Burnet, of the University of Cambridge, are leading a large multi-centre UK study designed to identify the common genetic variations that are associated with such side effects. The study - Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER) - is funded by Cancer Research UK and aims to extract DNA from the blood samples of 2,200 patients with a variety of cancers.

Dr West explains: "This is a very exciting development in cancer research. Genotyping studies should provide a means of identifying radiosensitive patients and lead to a greater individualisation of radiation dose prescription to optimise tumour control while reducing toxicity."

Dr West and her team are also involved in a study of patients with soft tissue sarcoma (cancer in the muscles), a rare cancer that accounts for approximately 1% of adult cancers with around 1,200 cases in the UK each year, again funded by Cancer Research UK.

VORTEX - led by Dr Martin Robinson at the University of Sheffield - is a randomised trial to assess if reducing post-operative radiotherapy in patients with soft tissue sarcoma (cancer of the muscle) increases their limb function without compromising the treatment. The Manchester team are using samples from VORTEX to carry out VORTEX-BIOBANK, a study that aims to develop a tumour profile that will identify patients with an increased likelihood of secondary cancer. The team also aims to investigate associations between common genetic variation and a patient's risk of radiation induced side-effects in this particular cancer, as they are doing for a variety of other cancers in RAPPER.

Miss Rebecca Elliott, who will make a presentation about the team's work at the conference today, says: "There is exciting high-throughput technology out there and we are looking at the possibility of individualising patient treatment. The technology allows us to look at the variation and expression of genes to see which genes indicate who will be sensitive to radiotherapy. In future we will have a patient profile - if you have certain versions of genes x, y and z, then you have the chance of getting toxicity one hundred times more than someone with other versions."

"Although we are still collecting samples and are some way off getting our final results, it is an important new pathway in cancer research."


'/>"/>

Contact: Mikaela Sitford
Mikaela.Sitford@manchester.ac.uk
07-768-980-942
University of Manchester
Source:Eurekalert

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , ... August 23, 2017 , ... ... to support long-term strategic growth plans, announcing the hiring of Kevin Keelan as ... technology consultant and seasoned sales manager, Keelan will be working with Virsys12 senior ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... accessible luxurious collection of unique masks and serums that perfectly fuse the beauty ... care advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... ... ... Glass is new to the Texas market, but is proudly managed by widely recognized All ... models, in Grand Prairie, TX, located in the center of the DFW Metroplex, the fourth ... for the past 40 years with 32 convenient locations in Texas, Nevada and California resulting ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... “Covert Awakening” is the creation of published author, Julianne Hale, a consultant ... as a policy and counter-terrorism expert focusing on the Near East region. ...
Breaking Medicine News(10 mins):
(Date:8/18/2017)... SEATTLE , Aug. 18, 2017  Nortis today ... provide funding for the third year of a Small ... the National Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ... ...
(Date:8/15/2017)...   Mostyn Law and Gulf Coast Regional Blood Center ... . The Mostyn Law family has had 3 members ... why Mostyn Law is partnering with Gulf Coast Regional ... appreciation. Blood supplies are running low. Gulf Coast Regional ... needs in August. That is why the blood center reached out ...
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
Breaking Medicine Technology: